ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice
Open Access
- 26 May 2016
- Vol. 4, e2081
- https://doi.org/10.7717/peerj.2081
Abstract
Cannabidiol (CBD) is currently being investigated as a novel therapeutic for the treatment of CNS disorders like schizophrenia and epilepsy. ABC transporters such as P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp) mediate pharmacoresistance in these disorders. P-gp and Bcrp are expressed at the blood brain barrier (BBB) and reduce the brain uptake of substrate drugs including various antipsychotics and anticonvulsants. It is therefore important to assess whether CBD is prone to treatment resistance mediated by P-gp and Bcrp. Moreover, it has become common practice in the drug development of CNS agents to screen against ABC transporters to help isolate lead compounds with optimal pharmacokinetic properties. The current study aimed to assess whether P-gp and Bcrp impacts the brain transport of CBD by comparing CBD tissue concentrations in wild-type (WT) mice versus mice devoid of ABC transporter genes. P-gp knockout (Abcb1a/b−∕−), Bcrp knockout (Abcg2−∕−), combined P-gp/Bcrp knockout (Abcb1a/b−∕−Abcg2−∕−) and WT mice were injected with CBD, before brain and plasma samples were collected at various time-points. CBD results were compared with the positive control risperidone and 9-hydroxy risperidone, antipsychotic drugs that are established ABC transporter substrates. Brain and plasma concentrations of CBD were not greater in P-gp, Bcrp or P-gp/Bcrp knockout mice than WT mice. In comparison, the brain/plasma concentration ratios of risperidone and 9-hydroxy risperidone were profoundly higher in P-gp knockout mice than WT mice. These results suggest that CBD is not a substrate of P-gp or Bcrp and may be free from the complication of reduced brain uptake by these transporters. Such findings provide favorable evidence for the therapeutic development of CBD in the treatment of various CNS disorders.Keywords
Funding Information
- University of Sydney Bridging Grant
- Bosch Translational Grant-in-Aid
- Brain & Behaviour Research Foundation
- Australian Postgraduate Award scholarship
This publication has 68 references indexed in Scilit:
- Acetaminophen Inhibits Intestinal P-Glycoprotein Transport ActivityJournal of Pharmaceutical Sciences, 2013
- Cannabidiol changes P-gp and BCRP expression in trophoblast cell linesPeerJ, 2013
- Enhanced Brain Disposition and Effects of Δ9-Tetrahydrocannabinol in P-Glycoprotein and Breast Cancer Resistance Protein Knockout MicePLOS ONE, 2012
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2012
- Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomesLife Sciences, 2011
- In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoproteinLife Sciences, 2010
- Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In VivoJournal of Pharmacology and Experimental Therapeutics, 2009
- The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarinBritish Journal of Pharmacology, 2008
- The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoidsBritish Journal of Pharmacology, 2007
- Multidrug resistance and the role of P-glycoprotein knockout miceEuropean Journal of Cancer, 1995